Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
about
Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic reviewAdverse effects of biologics: a network meta-analysis and Cochrane overviewPsoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatmentMaking the next steps in psoriatic arthritis management: current status and future directionsIdentifying a novel locus for psoriatic arthritisMeasures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureNew targets in psoriatic arthritisThe Changing Face of Clinical Trials in Psoriatic Arthritis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis.The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesWork-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysisWorking status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.Case report: Infliximab treatment in two Chinese patients with psoriatic arthritis.Spondyloarthritides: evolving therapiesInfliximab in the treatment of plaque type psoriasis.Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationThe risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Infliximab: 12 years of experienceUpdated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate.Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.
P2860
Q21090146-C6786AFC-4214-430F-A2D5-A3F4B2E38003Q24234197-1042D848-D77B-4A75-AC90-FDAED9D44411Q24813979-91DC3084-743E-4042-92E8-61D7CE1450CAQ26783506-9952F1D9-1CA0-459F-8857-02FAD540C45EQ26800688-35CBE820-4AEC-4445-88AC-4BDA9E427CF7Q26862017-3665C167-F64D-4AB0-8130-EF5535D8FE78Q27012134-384ABFEE-0AD9-45F7-9935-2CA934380BB3Q28069592-F3F48489-7100-495C-85F9-B0B18CDB794DQ30235002-519C60C3-9B04-475B-A3F4-6C98E98C2DA4Q30240183-CEDC0F54-73EA-4CAE-B7A1-C04E6483092AQ30240212-7CF710B0-56A2-472B-A86C-12214A640AFBQ30399745-2536554F-F16B-41A6-915C-04F75C0FB323Q30612910-B34AF4FC-CE9E-48D6-8712-449A6C93C9BDQ30675199-77E6F5AD-9A4C-4A3C-B7AC-83402182E95AQ30715455-81925993-566C-42EA-A1D4-E7B27C806852Q33554356-7D52E9A0-58A0-470E-9681-F81814EEAFEEQ33916770-7F0152A3-22F4-41DB-A0AF-B9CD7AE77B33Q33936266-83B61C26-1A57-4A5C-AE3E-1DDAFA55F5F5Q33990812-5A8C75C8-E357-4B9F-A710-229B1C58AFADQ34017619-02863759-FEBA-441C-A43A-919F7C9EBB64Q34176748-61C54C6A-5431-4972-9F99-6C66C31B2375Q34613907-F49560C5-AAB6-4B5E-973A-8B42DB6E72B5Q34620291-2648D67F-B787-45E1-84CE-339A33412CD1Q34620355-0A677032-0243-4CD5-823F-9CD032AB06DBQ34634463-E18A8F05-F7FB-4587-AA1D-401EC8030449Q34669637-0C24B768-8322-4F97-8545-C03EFA38B5B6Q34984568-B806DC4F-75E4-4D10-8C63-39263284BFE5Q35070446-41532895-5005-4366-AB27-1FF8F29389D2Q35579517-5A5A9851-A553-4603-B2E9-AC612E887C70Q35636900-CC15F794-5B0E-4D60-8810-D6F3AA6919A6Q35636983-0170D5E1-E92A-4669-8063-707936B7B661Q35760136-F5F40D21-D6C1-44DE-977C-061AADEA480DQ35760193-22CD500C-9B1A-4C8D-A2EB-CE20D86BC989Q35779864-5D66FC41-CC16-484B-A47D-67D7BB333ABDQ35819025-D42CD8E4-ABDC-4B39-B0E8-9DA7E6352A54Q35875481-91F9D6E5-5261-4509-A5F6-101228CCF6FFQ35937121-2F52D57D-6118-409C-AFD2-97585D78397FQ35953468-98641769-B46F-454E-8133-31D3A0FBCDA2Q36171750-51D850E3-0E50-4CD5-8DB2-86D09FE75E17Q36182383-1189196F-1700-4B74-9851-A27133F6607E
P2860
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@ast
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@en
type
label
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@ast
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@en
prefLabel
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@ast
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@en
P2093
P2860
P356
P1476
Infliximab improves signs and ...... results of the IMPACT 2 trial.
@en
P2093
A Kavanaugh
G G Krueger
IMPACT 2 Trial Investigators
L T Dooley
P2860
P304
P356
10.1136/ARD.2004.032268
P407
P577
2005-01-27T00:00:00Z